as 07-26-2024 4:00pm EST
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Founded: | 1999 | Country: | United States |
Employees: | N/A | City: | JERSEY CITY |
Market Cap: | 76.7M | IPO Year: | 2014 |
Target Price: | N/A | AVG Volume (30 days): | 127.7K |
Analyst Decision: | Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 2.04 | EPS Growth: | N/A |
52 Week Low/High: | $1.35 - $3.87 | Next Earning Date: | 08-12-2024 |
Revenue: | $140,385,000 | Revenue Growth: | 2436.77% |
Revenue Growth (this year): | -81.73% | Revenue Growth (next year): | 75.56% |
SCYX Breaking Stock News: Dive into SCYX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Associated Press Finance
3 months ago
GlobeNewswire
3 months ago
Simply Wall St.
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
6 months ago
The information presented on this page, "SCYX SCYNEXIS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.